Milstones

Over the past decade, PlexBio has been developing innovative technology platforms and investing in the field of precision medicine. Combined with Taiwan's mature semiconductor industry, we have developed the globally patented Precision Image Code Magnetic MicroDisc multiplex technological platform
2018
2018
2018. 10
PlexBio Received CE-IVD Mark for IntelliPlex™ Lung Cancer Panel

2018. 08
Received TFDA Licenses for IntelliPlex™ KRAS and KRAS+ Mutation Kits
Denka Signed Distribution Agreements with PlexBio for the IntelliPlex™ Instrument System and Reagents

2018. 05
Euroclone Signed Distribution Agreements with PlexBio for the IntelliPlex™ Instrument System and Reagent
University "G. D'Annunzio" of Chieti Presented Data on PlexBio Technology at Molecular Diagnostic Europe Conference

2018. 01
PlexBio received Deloitte Technology Fast 500 Asia Pacific recognition - Ranks Among Top Growing Companies in the Asia Pacific
PlexBio Expanded Collaboration with Denka to Co-Develop an Infectious Disease Diagnostic System
2017
2017
2017. 12
IntelliPlex™ HCV Genotyping Kit finished clinical trial, began database lock
Passed ISO 13485:2003 SGS auditing- received certification renewal

2017. 11
Received CE-IVD approval for IntelliPlex™ ROS 1, RET/NTRK1 Rearrangement Kit, IntelliPlex™ KRAS Plus Mutation Kit, IntelliPlex™NRAS Mutation Kit

2017. 09
Received CE-IVD approval for IntelliPlex™ 1000 πCode Processor

2017. 04
Received CE-IVD approval for IntelliPlex™ ALK Rearrangement Kit and HPV Genotyping Kits
PlexBio made its debut in presenting IntelliPlex CE-IVD reagents and test results to the scientific community at Molecular Diagnostics Europe conference

2017 03
Received TFDA certification for IntelliPlex™ 1000 πCode Processor

2017. 02
Received TFDA certification for PlexBio™ 100 Fluorescent Analyzer 100 Fluorescent Analyzer
 
2016
2016
2016. 09
 License agreements signed with Denka Seiken Co.. Ltd.

2016. 02
Listed company at Taiwan emerging stock market

2016. 01
Supplemental public issuance took effect
Completed nCode MicroDisc development
2015
2015
2015. 11
Completed a round of fund-raising of NTD $350 million at $35 per share; total of NTD $508 million paid-in capital was rais

2015. 04
Obtained CE certificates for bDNA HPV ~ KRAS ' BRAF ~ EGFR and wash station
KRAS clinical trial began

2015. 02
Introduced PlexBo Wash Station

2015. 01
FISH Probe Kit passed ISO 9001 and ISO 13485
Obtained TFDA's approval for TERC and HERZ
2014
2014
2014. 12
Obtained CFDA's import license for PlexBio Analyzer
Qualified for GMP Production of IHC reagents and Kits

2014. 02
Complete a round of fund-raising of NTD $272 million at $22 per share, total of NTD $380 million paid-in capital was raised
 
2013
2013
2013. 12
Establishment of Jiangsu PlexBio Medical Technology Co., Limited. Introduced PlexBio Thermocycler

2013. 08
Obtained TFDA's approval for PlexBio Analyzer

2013. 07
Obtained ISO 9001, ISO 13485, GMP, and CE Certifications for PlexBio Analyzer

2013. 04
Completed a round of Fundraising of NTD $97 million at $15 per share; Total of NTD $270 million paid-in capital was raised

2013. 03
Introduced PlexBio 100 Analyzer and PlexBio Thermo Shaker

 
2012
2012
2012. 12
Introduced ISO/GMP quality systems and certified plant

2012. 04
Introduced PlexBio 100 Analyzer and PlexBio Thermo Shaker

 
2011
2011
2011. 12
Establishment of Research Centers for Applied Proteomics

2011. 10
Collaborated with Cathy general Hospital to complete a clinical trial on the screening of diagnostic reagent in 150 HPV cases, which paved the way for subsequent development of IntelliPlex series using digital analyzer phase I.

2011. 04
Signed a contract with the Instrument Technology Research Center of the Nation Research Laboratory (NAR Lab) in July 2011 to develop digital analyzer phase I


 
2010
2010
2010. 10
Completed factory set-up registration
Establishment of HongKong Co., Limited

2010. 06
Establishment of HongKong Co., Limited

 
2009
2009
2009. 12
 PlexBio Co., Ltd was established with a registered capital of $52,600,000 NT

您目前為透過後台登入模式

Please Enable cookies to improve your user experience

Continue